Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Fortis shareholders...

    Fortis shareholders vote out Brian Tempest from Board

    Written by Ruby Khatun Khatun Published On 2018-05-24T13:25:19+05:30  |  Updated On 24 May 2018 1:25 PM IST
    Fortis shareholders vote out Brian Tempest from Board

    New Delhi: Fortis Healthcare said its shareholders have voted in favour of removal of Brian Tempest from the Board of Directors in the company's extraordinary general meeting(EGM) held on Tuesday.


    Tempest is among the four directors of cash-strapped healthcare chain whose removals were sought by two institutional investors. Three directors -- Harpal Singh, Sabina Vaisoha, and Tejinder Singh Shergill -- had already resigned before the EGM.


    Read also: Two more Fortis directors quit ahead of crucial EGM today

    Independent director quits Fortis board ahead of stakeholders meet

    The development has cast a shadow over the ongoing attempt to sell Fortis as these four directors were among the five who had voted in favour of Munjals-Burmans' Rs 1,800 crore bid for the healthcare firm.


    The board of Fortis on May 10 in a 5-3 decision opted to go with the offer from Munjals-Burmans combine. In a regulatory filing, Fortis said the resolution for the removal of Tempest as director of the company was passed with the requisite majority with 87.91 percent votes in favour.


    Read also: Battle For Fortis: Munjal-Burmans emerge Victorious

    Tempest has been a long time associate of the erstwhile promoters of Fortis Healthcare, the Singh brothers through their earlier business Ranbaxy, which they later sold to Japan's Daiichi Sankyo.


    He started working for Ranbaxy Laboratories in 1995 and held various positions including Managing Director and CEO, till he retired in 2008 as chief mentor, vice-chairman and non-executive director.


    Fortis, in the filing, said as the three other directors had tendered their resignations prior to the EGM and thereby ceased to be directors of the company, "accordingly, the said resolutions for their removal become infructuous."


    On the other hand, Fortis said its shareholders have voted in favour of appointments of Suvalaxmi Chakraborty, Ravi Rajagopal, and Indrajit Banerjee as independent directors on the board.


    While seeking removal of the four directors, National Westminster Bank Plc as trustee of Jupiter India Fund and East Bridge Capital Master Fund had also sought appointment of these three new independent directors.


    The two institutional investors, which together hold 12.04 percent stake in Fortis Healthcare, had demanded the removal of the four directors last month alleging that they failed to work in the interest of all shareholders, particularly in their handling of the hospital chain's proposed sale. Fortis is in the process of inducting new investor to the company, having opted for the Munjals-Burmans combine offer although rivals are keeping the race alive.


    There were five suitors in the race for Fortis, including TPG-Manipal combine, Malaysia's IHH Healthcare and KKR-backed Radiant Life Care, which gave binding offers. China's Fosun Healthcare did not make a binding bid for the company.


    IHH Healthcare has extended its revised offer for Fortis till May 29 after which it shall lapse. IHH Healthcare had increased its offer to directly invest in Fortis at Rs 175 per share on May 1. It had initially made a non-binding offer to invest in Fortis at Rs 160 per share.


    Read also: IHH Healthcare extends acceptance period of enhanced revised offer for Fortis
    boardboard of directorsBrian TempestDaiichi SankyoEGMextraordinary general meetingFortisFortis HealthcareRanbaxy laboratoriesremovalshareholdersSingh brothersvote out
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok